Track: CME Session
Track: Hybrid Session
Katy Beckermann, MD, PhD
Vanderbilt University Medical Center
Disclosure(s): Contract Research: Aravive (Ongoing); Arrowhead (Ongoing); Aveo Oncology (Ongoing); Bristol Meyers Squibb (Ongoing); Corvus (Ongoing); Exelixis (Ongoing); Merck (Ongoing)
Non-CE Consulting: Aravive (Ongoing); Aveo Oncology (Ongoing); Bristol Meyers Squibb (Ongoing); Exelixis (Ongoing)
Non-CE Speakers Bureau: Sanofi (Ongoing); SeaGen (Ongoing)
Daniel YC Heng, MD
Tom Baker Cancer Centre, Calgary, AB, Canada, United States
Disclosure(s): Non-CE Consulting: Eisai (Ongoing); Ipsen (Ongoing); Merck (Ongoing); Novartis (Ongoing); Pfizer (Ongoing)
Speaker: Katy Beckermann, MD, PhD – Vanderbilt University Medical Center
Speaker: Daniel YC Heng, MD – Tom Baker Cancer Centre, Calgary, AB, Canada
Speaker: Ari Hakimi – Memorial Sloan Kettering Cancer Center